GeoVax Labs (GOVX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on vaccines and immunotherapies for infectious diseases and solid tumor cancers, leveraging proprietary MVA-based platforms.

• Lead programs include a next-generation COVID-19 vaccine (GEO-CM04S1), an oncolytic gene therapy for head and neck cancer (Gedeptin®), and a Mpox/smallpox vaccine (GEO-MVA).

• Pipeline includes preclinical candidates for Ebola, Marburg, and Zika, with strategic emphasis on advancing candidates through clinical trials and partnering for commercialization.

• Holds over 135 granted or pending patents across 23 patent families, with a mix of wholly owned, co-owned, and in-licensed IP.

Financial performance and metrics

• No product revenue to date; revenue derived from government grants and contracts.

• Net loss of $25.0 million for 2024 and $17.0 million for the nine months ended September 30, 2025.

• Research and development expenses were $23.7 million in 2024, up 14% from 2023, with a decrease in R&D expenses in 2025 due to contract termination.

• Cash and cash equivalents were $5.0 million as of September 30, 2025; working capital of $4.7 million.

• Received a going concern opinion from auditors, reflecting substantial doubt about ability to continue without additional funding.

Use of proceeds and capital allocation

• Estimated net proceeds of $6.8 million from the offering, after fees and expenses.

• Proceeds intended for advancement of product candidates, including R&D, manufacturing, clinical studies, capital expenditures, and working capital.

• Management has broad discretion over use of funds; actual allocation may vary based on operational needs.